Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93


Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.

Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3731-41.


Effect of anti-DR5 and chemotherapy on basal-like breast cancer.

Oliver PG, LoBuglio AF, Zhou T, Forero A, Kim H, Zinn KR, Zhai G, Li Y, Lee CH, Buchsbaum DJ.

Breast Cancer Res Treat. 2012 Jun;133(2):417-26. doi: 10.1007/s10549-011-1755-0. Epub 2011 Sep 7.


Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody.

Kim H, Morgan DE, Zeng H, Grizzle WE, Warram JM, Stockard CR, Wang D, Zinn KR.

Radiology. 2008 Sep;248(3):844-51. doi: 10.1148/radiol.2483071740.


Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ.

Clin Cancer Res. 2008 Apr 1;14(7):2180-9. doi: 10.1158/1078-0432.CCR-07-1392.


Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.

DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, Vickers SM.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5535s-5543s.


Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.

Bevis KS, McNally LR, Sellers JC, Della Manna D, LondoƱo Joshi A, Amm H, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2011 Apr;121(1):193-9. doi: 10.1016/j.ygyno.2010.11.046. Epub 2011 Jan 5.


Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.

Fiveash JB, Gillespie GY, Oliver PG, Zhou T, Belenky ML, Buchsbaum DJ.

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):507-16. doi: 10.1016/j.ijrobp.2008.02.005.


DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy.

Kim H, Folks KD, Guo L, Stockard CR, Fineberg NS, Grizzle WE, George JF, Buchsbaum DJ, Morgan DE, Zinn KR.

Mol Imaging Biol. 2011 Feb;13(1):94-103. doi: 10.1007/s11307-010-0320-2.


Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.

DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM.

J Gastrointest Surg. 2006 Nov;10(9):1291-300; discussion 1300.


Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

Kim H, Zhai G, Samuel SL, Rigell CJ, Umphrey HR, Rana S, Stockard CR, Fineberg NS, Zinn KR.

Mol Cancer Ther. 2012 Feb;11(2):405-15. doi: 10.1158/1535-7163.MCT-11-0581. Epub 2011 Dec 27.


Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.

Frederick PJ, Kendrick JE, Straughn JM Jr, Della Manna DL, Oliver PG, Lin HY, Grizzle WE, Stockard CR, Alvarez RD, Zhou T, LoBuglio AF, Buchsbaum DJ.

Int J Gynecol Cancer. 2009 Jul;19(5):814-9. doi: 10.1111/IGC.0b013e3181a2a003.


Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy.

Zhai G, Kim H, Sarver D, Samuel S, Whitworth L, Umphrey H, Oelschlager DK, Beasley TM, Zinn KR.

J Magn Reson Imaging. 2014 Jun;39(6):1588-94. doi: 10.1002/jmri.24319. Epub 2013 Oct 22.


Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.

Straughn JM Jr, Oliver PG, Zhou T, Wang W, Alvarez RD, Grizzle WE, Buchsbaum DJ.

Gynecol Oncol. 2006 Apr;101(1):46-54. Epub 2005 Nov 4.


Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

Kim H, Samuel SL, Zhai G, Rana S, Taylor M, Umphrey HR, Oelschlager DK, Buchsbaum DJ, Zinn KR.

Cancer Biol Ther. 2014 Aug;15(8):1053-60. doi: 10.4161/cbt.29183.


Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.

Kendrick JE, Straughn JM Jr, Oliver PG, Wang W, Nan L, Grizzle WE, Stockard CR, Alvarez RD, Buchsbaum DJ.

Gynecol Oncol. 2008 Mar;108(3):591-7. doi: 10.1016/j.ygyno.2007.11.039. Epub 2008 Jan 4.


Quantitative mapping of tumor vascularity using volumetric contrast-enhanced ultrasound.

Hoyt K, Sorace A, Saini R.

Invest Radiol. 2012 Mar;47(3):167-74. doi: 10.1097/RLI.0b013e318234e6bc.


Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.

Pƶschinger T, Renner A, Eisa F, Dobosz M, Strobel S, Weber TG, Brauweiler R, Kalender WA, Scheuer W.

Invest Radiol. 2014 Jul;49(7):445-56. doi: 10.1097/RLI.0000000000000038.


Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.

Kim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE, Warram JM, Stockard CR, McNally LR, Long JW, Sellers JC, Forero A, Zinn KR.

Cancer Res. 2008 Oct 15;68(20):8369-76. doi: 10.1158/0008-5472.CAN-08-1771.


Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.

Amm HM, Zhou T, Steg AD, Kuo H, Li Y, Buchsbaum DJ.

Mol Cancer Res. 2011 Apr;9(4):403-17. doi: 10.1158/1541-7786.MCR-10-0133. Epub 2011 Feb 25.

Supplemental Content

Support Center